Breaking Down Viridian Therapeutics: 10 Analysts Share Their Views
Breaking Down Viridian Therapeutics: 10 Analysts Share Their Views
深入解析Viridian Therapeutics：10位分析師分享他們的觀點
The perception of...10 analysts have expressed a variety of opinions on Viridian Therapeutics (NASDAQ:VRDN) over the past quarter, offering a diverse set of opinions from bullish to bearish.
在過去一個季度中，10位分析師對維裏迪安治療公司（納斯達克：VRDN）發表了多種觀點，提供了一系列從看好到看淡的意見。
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
下表總結了他們近期的評級，揭示了過去30天內情緒的變化，並與之前幾個月進行了比較。
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $41.2, a high estimate of $61.00, and a low estimate of $34.00. Witnessing a positive shift, the current average has risen by 3.78% from the previous average price target of $39.70.
分析師評估的12個月價格目標揭示了進一步的見解，平均目標爲41.2美元，最高估計爲61.00美元，最低估計爲34.00美元。看到一個積極的變化，目前的平均值比之前的39.70美元的平均價格目標上升了3.78%。
Investigating Analyst Ratings: An Elaborate Study
分析師評級的調查：一項詳盡的研究
The perception of...
金融專...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。